Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.53 - $2.89 $2.48 Million - $4.69 Million
-1,621,300 Reduced 37.09%
2,750,000 $5.03 Million
Q1 2022

May 16, 2022

SELL
$2.67 - $4.68 $5.16 Million - $9.04 Million
-1,931,725 Reduced 30.65%
4,371,300 $11.7 Million
Q3 2021

Nov 15, 2021

SELL
$4.32 - $6.43 $392,580 - $584,326
-90,875 Reduced 1.42%
6,303,025 $32.1 Million
Q2 2021

Aug 16, 2021

BUY
$6.33 - $9.91 $372,837 - $583,699
58,900 Added 0.93%
6,393,900 $40.5 Million
Q1 2021

May 17, 2021

BUY
$6.6 - $9.0 $41 Million - $55.9 Million
6,210,000 Added 4968.0%
6,335,000 $49 Million
Q4 2020

Feb 16, 2021

BUY
$6.47 - $7.9 $808,750 - $987,500
125,000 New
125,000 $819,000
Q3 2020

Nov 16, 2020

SELL
$6.55 - $8.83 $6.77 Million - $9.12 Million
-1,033,406 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$7.4 - $14.64 $6.04 Million - $12 Million
816,842 Added 377.18%
1,033,406 $8.61 Million
Q1 2020

May 15, 2020

SELL
$3.61 - $8.6 $1.82 Million - $4.34 Million
-504,436 Reduced 69.96%
216,564 $1.66 Million
Q4 2019

Feb 14, 2020

BUY
$5.17 - $8.91 $3.73 Million - $6.42 Million
721,000 New
721,000 $5.99 Million
Q3 2019

Nov 15, 2019

SELL
$7.38 - $12.25 $2.44 Million - $4.05 Million
-330,498 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$9.35 - $11.41 $2.76 Million - $3.37 Million
-295,151 Reduced 47.18%
330,498 $3.71 Million
Q1 2019

May 15, 2019

SELL
$9.5 - $19.16 $7.96 Million - $16.1 Million
-838,147 Reduced 57.26%
625,649 $6.73 Million
Q4 2018

Feb 14, 2019

BUY
$12.69 - $18.61 $1.73 Million - $2.53 Million
136,056 Added 10.25%
1,463,796 $22.1 Million
Q3 2018

Nov 14, 2018

BUY
$18.04 - $26.41 $21.1 Million - $30.9 Million
1,169,569 Added 739.43%
1,327,740 $24.6 Million
Q2 2018

Aug 14, 2018

BUY
$21.38 - $29.68 $3.38 Million - $4.69 Million
158,171 New
158,171 $3.62 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $69.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.